Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2015 · 10-Q
Revenue$1.71M$1.71M+19.5% vs Q2 2014 Net Income-$157.23K-$157.23KN/M vs Q2 2014 EPS, diluted—
Gross Profit$823,130+18.2% Operating Income-$157,529N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$159,480N/M Margins · derivedGross margin48.3%−0.6 pt vs Q2 2014
Operating margin-9.2%+4.8 pt vs Q2 2014
Net margin-9.2%+4.8 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 11, 2015 · 42 d after period end